CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Negroni, A.
Right arrow Articles by Raschella, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Negroni, A.
Right arrow Articles by Raschella, G.

Cell Growth & Differentiation, Vol 2, Issue 10 511-518, Copyright © 1991 by American Association of Cancer Research


ARTICLES

Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line

A Negroni, S Scarpa, A Romeo, S Ferrari, A Modesti and G Raschella
Division of Physics and Biochemical Sciences, Ente per le nuove technologie per l'energia e l'ambiente (ENEA), Rome, Italy.

The effects of an antisense oligodeoxynucleotide to codons 2-7 of the oncogene MYCN on the human neuroblastoma cell line LAN-5 were studied. Treated cells showed a decreased MYCN protein expression and synthesis by immunoperoxidase staining and immunoprecipitation. At the same time, the replication rate was inhibited, and the phenotype was modified toward a more differentiated type. Our data suggest the involvement of oncogene MYCN in both proliferative and differentiative processes.


This article has been cited by other articles:


Home page
Mol Cancer ResHome page
M. Petroni, V. Veschi, A. Prodosmo, C. Rinaldo, I. Massimi, M. Carbonari, C. Dominici, H. P. McDowell, C. Rinaldi, I. Screpanti, et al.
MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response
Mol. Cancer Res., January 1, 2011; 9(1): 67 - 77.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
E. A. Beierle, A. Trujillo, A. Nagaram, E. V. Kurenova, R. Finch, X. Ma, J. Vella, W. G. Cance, and V. M. Golubovskaya
N-MYC Regulates Focal Adhesion Kinase Expression in Human Neuroblastoma
J. Biol. Chem., April 27, 2007; 282(17): 12503 - 12516.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Chesler, C. Schlieve, D. D. Goldenberg, A. Kenney, G. Kim, A. McMillan, K. K. Matthay, D. Rowitch, and W. A. Weiss
Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma
Cancer Res., August 15, 2006; 66(16): 8139 - 8146.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Giannini, F. Cerignoli, M. Mellone, I. Massimi, C. Ambrosi, C. Rinaldi, C. Dominici, L. Frati, I. Screpanti, and A. Gulino
High Mobility Group A1 Is a Molecular Target for MYCN in Human Neuroblastoma
Cancer Res., September 15, 2005; 65(18): 8308 - 8316.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. Tonelli, S. Purgato, C. Camerin, R. Fronza, F. Bologna, S. Alboresi, M. Franzoni, R. Corradini, S. Sforza, A. Faccini, et al.
Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis
Mol. Cancer Ther., May 1, 2005; 4(5): 779 - 786.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. M. Hansford, W. D. Thomas, J. M. Keating, C. A. Burkhart, A. E. Peaston, M. D. Norris, M. Haber, P. J. Armati, W. A. Weiss, and G. M. Marshall
Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification
PNAS, August 24, 2004; 101(34): 12664 - 12669.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn
Advances in the Diagnosis and Treatment of Neuroblastoma
Oncologist, June 1, 2003; 8(3): 278 - 292.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. K. Matthay
MYCN Expression in Neuroblastoma: A Mixed Message?
J. Clin. Oncol., November 1, 2000; 18(21): 3591 - 3594.
[Full Text] [PDF]


Home page
JCOHome page
S. L. Cohn, W. B. London, D. Huang, H. M. Katzenstein, H. R. Salwen, T. Reinhart, J. Madafiglio, G. M. Marshall, M. D. Norris, and M. Haber
MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN
J. Clin. Oncol., November 1, 2000; 18(21): 3604 - 3613.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. M. Maris and K. K. Matthay
Molecular Biology of Neuroblastoma
J. Clin. Oncol., July 1, 1999; 17(7): 2264 - 2264.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
G. Raschell, A. Negroni, A. Sala, S. Pucci, A. Romeo, and B. Calabretta
Requirement of B- myb Function for Survival and Differentiative Potential of Human Neuroblastoma Cells
J. Biol. Chem., April 14, 1995; 270(15): 8540 - 8545.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
C. F. Manohar, M. L. Short, A. Nguyen, N. N. Nguyen, D. Chagnovich, Q. Yang, and S. L. Cohn
HuD, a Neuronal-specific RNA-binding Protein, Increases the in Vivo Stability of MYCN RNA
J. Biol. Chem., January 11, 2002; 277(3): 1967 - 1973.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1991 by the American Association of Cancer Research.